Clinical Trials
32 trialsNCT01130519 2025-02-21
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02420821 2023-01-30
IMmotion151
Hoffmann-La Roche
Phase 3 Completed
NCT02348008 2022-09-14
Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:
Big Ten Cancer Research Consortium
Phase 1/2 Completed
NCT01664182 2022-06-07
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00112840 2022-02-01
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01399918 2022-02-01
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00113217 2020-09-23
Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01984242 2019-12-23
IMmotion150
Hoffmann-La Roche
Phase 2 Completed
NCT00853021 2019-06-05
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01198158 2019-03-06
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00378703 2018-11-14
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01727089 2018-08-28
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00923130 2018-04-17
Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00782275 2018-01-24
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00496587 2017-07-19
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00934440 2017-06-14
5-AZ
University of Kansas Medical Center
Phase 1/2 Terminated
NCT00651482 2017-04-11
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
Stanford University
Phase 2 Terminated
NCT00719264 2017-03-20
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis
Phase 2 Completed
NCT02627144 2016-08-29
Bevacizumab in Metastatic Renal Cancer
Hoffmann-La Roche
Completed
NCT00738530 2016-06-23
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Hoffmann-La Roche
Phase 3 Completed
NCT00631371 2016-04-27
INTORACT
Pfizer
Phase 3 Completed
NCT00324870 2016-01-13
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00913913 2015-12-01
Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
Dartmouth-Hitchcock Medical Center
Phase 2 Terminated
NCT00126490 2015-06-30
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00601926 2015-06-15
Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT00796757 2015-05-27
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Hoffmann-La Roche
Phase 2 Completed
NCT00126503 2015-01-15
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00520403 2014-10-13
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT00684996 2014-05-15
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00523640 2014-02-11
A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
University of Chicago
Phase 2 Terminated
NCT00193258 2013-01-31
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00491738 2009-04-10
A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)
Genentech, Inc.
Phase 2 Terminated